An association between mutation load and response to immune checkpoint inhibitors (CTLA-4 blocking agents in this case) was first observed in studies of ipilimumab in advanced melanoma [19,20], raising the possibility that the genetic landscape of a tumour may affect the clinical benefit provided by immunotherapies. The gene discussed is CTLA4; the disease is neoplasm.